Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott to acquire Ibis Biosciences
In addition to the closing purchase price, Isis will receive earn out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits. Abbott
In addition to the closing purchase price, Isis will receive earn out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits. Abbott
The open-label, US Phase I-II study evaluated prostate cancer patients who had failed standard hormonal therapies, including men who had also failed standard chemotherapy regimens. A total of
The overall goal of the cooperative R&D agreement (CRADA), which will involve researchers from Uniformed Services University of the Health Sciences’s (USU) infectious disease clinical research program (IDCRP)
As part of the collaboration, the J Craig Venter Institute (JCVI) has purchased a Barocycler NEP2320 PCT sample preparation system. The company also announced that it has sold
Under terms of the agreement, Novo Nordisk and VLST will jointly undertake a research program to identify collaboration targets and develop product candidates within the field of autoimmune
Based on standard 802.11b Wi-Fi technology, R Series defibrillators equipped with Wi-Fi automatically send an alert when their state of readiness is compromised. Early notification maximizes patient safety
This restructuring will provide both additional cash to Remedent as well as the elimination of all current and future overhead of the OTC division. The restructuring involved a
Previously these patients began Sprycel therapy with a dose of 70mg taken twice daily. The once a day dosing simplifies treatment for patients and the lower dose offers
Biovitrum’s payment to Amgen is $117 million of which $13 million was paid at signing on September 12, 2008. The remaining $104 million has been paid in cash,
The trial has also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005). Adlea is a non-opioid